Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1992 1
1994 1
1997 1
2001 2
2004 3
2005 1
2009 1
2011 2
2012 3
2013 3
2015 1
2016 4
2017 7
2018 6
2019 7
2020 8
2021 9
2022 9
2023 8
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis.
Reiter A, George TI, Gotlib J. Reiter A, et al. Blood. 2020 Apr 16;135(16):1365-1376. doi: 10.1182/blood.2019000932. Blood. 2020. PMID: 32106312 Free article. Review.
Sensitive detection of the recurrent KIT D816V mutation and use of next-generation sequencing (NGS) panels to profile the genetic landscape of SM variants have been critical adjuncts to the diagnosis and subclassification of SM, and development of clinical-molecular prognostic …
Sensitive detection of the recurrent KIT D816V mutation and use of next-generation sequencing (NGS) panels to profile the genetic landscape …
New Insights into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy.
Valent P, Akin C, Sperr WR, Horny HP, Arock M, Metcalfe DD, Galli SJ. Valent P, et al. Annu Rev Pathol. 2023 Jan 24;18:361-386. doi: 10.1146/annurev-pathmechdis-031521-042618. Epub 2022 Oct 21. Annu Rev Pathol. 2023. PMID: 36270293 Free article. Review.
The genetic background, additional somatic mutations, and comorbidities also contribute to the course and prognosis. Patients with SM may also suffer from mediator-related symptoms or even an MC activation syndrome. ...
The genetic background, additional somatic mutations, and comorbidities also contribute to the course and prognosis. Patients …
Blinatumomab in Practice.
Lantz J, Pham N, Jones C, Reed D, El Chaer F, Keng M. Lantz J, et al. Curr Hematol Malig Rep. 2024 Feb;19(1):1-8. doi: 10.1007/s11899-023-00714-7. Epub 2023 Dec 7. Curr Hematol Malig Rep. 2024. PMID: 38060085 Review.
PURPOSE OF REVIEW: Acute lymphoblastic leukemia (ALL) is a rare hematologic neoplasm in adults, with most cases defined by pathology related to abnormal B cell proliferation known as B-cell ALL. The course is challenging, with less-than-optimal survival outcomes, even with …
PURPOSE OF REVIEW: Acute lymphoblastic leukemia (ALL) is a rare hematologic neoplasm in adults, with most cases defined by pathology related …
Avapritinib for Systemic Mastocytosis.
Bose P, Verstovsek S. Bose P, et al. Expert Rev Hematol. 2021 Aug;14(8):687-696. doi: 10.1080/17474086.2021.1959315. Epub 2021 Aug 6. Expert Rev Hematol. 2021. PMID: 34289787
AdvSM, comprising aggressive SM, SM with an associated hematologic neoplasm and mast cell leukemia, however, carries a poor prognosis. Avapritinib is a highly potent and selective inhibitor of mutant KIT. ...
AdvSM, comprising aggressive SM, SM with an associated hematologic neoplasm and mast cell leukemia, however, carries a poor prognosis …
Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice.
Valent P, Hartmann K, Schwaab J, Alvarez-Twose I, Brockow K, Bonadonna P, Hermine O, Niedoszytko M, Carter MC, Hoermann G, Sperr WR, Butterfield JH, Ustun C, Zanotti R, Radia DH, Castells M, Triggiani M, Schwartz LB, Orfao A, George TI, Sotlar K, Gotlib J, Reiter A, Horny HP, Arock M, Akin C, Metcalfe DD. Valent P, et al. J Allergy Clin Immunol Pract. 2022 Aug;10(8):1999-2012.e6. doi: 10.1016/j.jaip.2022.03.007. Epub 2022 Mar 25. J Allergy Clin Immunol Pract. 2022. PMID: 35342031 Free article. Review.
Patients with indolent SM have a normal to near-normal life expectancy, whereas patients with advanced SM, including aggressive SM and MC leukemia, have a poor prognosis. In those with advanced SM, multiple somatic mutations and an associated hematologic neoplasm may be de …
Patients with indolent SM have a normal to near-normal life expectancy, whereas patients with advanced SM, including aggressive SM and MC le …
Relevant updates in systemic mastocytosis.
Coltoff A, Mascarenhas J. Coltoff A, et al. Leuk Res. 2019 Jun;81:10-18. doi: 10.1016/j.leukres.2019.04.001. Epub 2019 Apr 4. Leuk Res. 2019. PMID: 30978435 Review.
The symptoms and clinical presentation of SM are the result of both MC proliferation as well as activation and degranulation, causing hyperactive and over-exaggerated hypersensitivity responses, as well as organ infiltration by pathogenic MCs. The clinical presentation and cou …
The symptoms and clinical presentation of SM are the result of both MC proliferation as well as activation and degranulation, causing hypera …
Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts.
Valent P, Akin C, Arock M, Gleixner KV, Greinix H, Hermine O, Horny HP, Ivanov D, Orfao A, Rabitsch W, Reiter A, Schulenburg A, Sotlar K, Sperr WR, Ustun C. Valent P, et al. Int J Mol Sci. 2023 Oct 12;24(20):15125. doi: 10.3390/ijms242015125. Int J Mol Sci. 2023. PMID: 37894806 Free PMC article. Review.
Advanced systemic mastocytosis (SM) is a heterogeneous group of myeloid neoplasms characterized by an uncontrolled expansion of mast cells (MC) in one or more internal organs, SM-induced tissue damage, and poor prognosis. Advanced SM can be categorized into aggressive SM ( …
Advanced systemic mastocytosis (SM) is a heterogeneous group of myeloid neoplasms characterized by an uncontrolled expansion of mast cells ( …
Update on diagnostic approaches and therapeutic strategies in systemic mastocytosis.
Radia DH, Moonim MT. Radia DH, et al. Best Pract Res Clin Haematol. 2022 Jun;35(2):101380. doi: 10.1016/j.beha.2022.101380. Epub 2022 Sep 14. Best Pract Res Clin Haematol. 2022. PMID: 36333068 Review.
These patients with advanced systemic mastocytosis have poor outcome; however, recent advances in diagnosis, molecular genetics and treatment have changed the prognostic landscape for this group of patients. In this review we address the most topical questions related to d …
These patients with advanced systemic mastocytosis have poor outcome; however, recent advances in diagnosis, molecular genetics and treatmen …
Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches.
Valent P, Akin C, Gleixner KV, Sperr WR, Reiter A, Arock M, Triggiani M. Valent P, et al. Int J Mol Sci. 2019 Jun 18;20(12):2976. doi: 10.3390/ijms20122976. Int J Mol Sci. 2019. PMID: 31216696 Free PMC article. Review.
Whereas patients with indolent forms of the disease have a normal or near-normal life expectancy, patients with advanced mast cell neoplasms, including aggressive SM and mast cell leukemia, have a poor prognosis with short survival times. In a majority of these patients, m …
Whereas patients with indolent forms of the disease have a normal or near-normal life expectancy, patients with advanced mast cell neoplasms …
75 results